Skip to main content
Premium Trial:

Request an Annual Quote

German Biochip Maker GeneScan Buys Stake in US Company

NEW YORK, April 11 – Biochip maker GeneScan of Freiburg Germany has acquired a minority stake in Oasis Biosciences of San Diego, Reuters reported Wednesday.

GeneScan, which paid $6 million for a “significant” holding in the company, also acquired the option to buy a majority stake in Oasis in one year’s time, Reuters said.

GeneScan acquired the stake in Oasis in order to gain a hold of its technology to improve the speed and reliability of biochips as it prepares to enter the pharmacogenomics sector.

GeneScan could not immediately be reached for comment.

In January, GeneScan announced that it had entered a deal to develop Motorola’s eSensor DNA detection system to detect genetically modified crops.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.